Skip to main content

Table 1 Baseline clinical characteristics of enrolled subjects

From: BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Clinical characteristics DM2 + CVD (n = 14) Controls (n = 12) p value
Age 68.39 (5.08) 68.09 (5.16) 0.9
Gender (male %) 7 (50) 8 (66.7) 0.7
BMI (mean (SD)) 31.06 (6.85) 26.71 (5.66) 0.09
Lifestyle
 Current smoker 0 (0) 0 (0) 1
 Former smoker 7 (50) 6 (50.0) 1
 Past smoker 7 (50) 6 (50.0) 1
 Pack-years (mean (SD)) 9.50 [0–45] 4.00 [0–10.5] 0.06
Systolic BP (mean (SD)) 142.93 (13.38) 127.5 (15.21) 0.01
Medical history
 AP (%) 7 (50) 0 (0) 0.02
 MI (%) 4 (28.6) 0 (0) 0.1
 CVA (%) 2 (14.3) 0 (0) 0.5
 PAD (%) 6 (42.9) 0 (0) 0.03
CRP (median [IQR]) 1.50 [1.30–3.15] 1.35 [0.85–2.02] 0.3
Leukocytes (mean (SD)) 6.59 (1.35) 5.57 (1.65) 0.1
Monocytes (mean (SD)) 0.56 (0.17) 0.50 (0.13) 0.4
Glucose (median [IQR]) 8,05 [7.30–10.15] 5.35 [5.20–5.60]  < 0.001
Creatinine (median [IQR]) 89.5 [84–113.75] 84.5 [66.5–92] 0.08
Total cholesterol (mean (SD)) 3.97 (0.77) 5.48 (1.21) 0.001
HDL cholesterol (mean (SD)) 1.31 (0.22) 1.73 (0.69) 0.04
LDL cholesterol (mean (SD)) 1.93 (0.47) 3.23 (0.79) < 0.001
Triglycerides (median [IQR]) 1.39 [1.13–1.70] 0.85 [0.71–1.29] 0.02
Lp(a) (median [IQR]) 103 [90–120.5] 87.5 [45.25–148.75] 0.9
Hba1c (median [IQR]) 63 [54.5–66.75] 38.5 [38–39.25] < 0.001
Statin use (%) 12 (85.7) 0 < 0.001
Insulin use (%) 10 (71.4) 0 0.001
  1. Data are presented as the mean (SD), median (IQR) or n (%)
  2. BMI body mass index, BP blood pressure, AP angina pectoris, MI myocardial infarction; CVA cerebrovascular accident, PAD peripheral arterial disease, CRP C-reactive protein, HDL high-density lipoprotein, LDL low-density lipoprotein; Lp(a) lipoprotein (a)